Glaucoma is one of the leading causes of blindness worldwide. It was estimated that in 2010, 60.5 million people had glaucoma and this was projected to increase to 79.6 million by 2020.
US OPHTHALMIC REVIEW punch is associated with complications, including iris prolapse and rapid evacuation of aqueous from the anterior chamber, which causes the chamber to shallow. In addition, patients undergoing the traditional trabeculectomy also have surgical iridectomies. There are inherent risks with iridectomies that include intraoperative bleeding, postoperative hyphema formation, monocular diplopia, and, if zonular dialysis is present, potentially vitreous prolapse through the iridectomy.
Glaucoma implants, known as aqueous shunts or glaucoma drainage devices, were initially developed for use in complex glaucoma patients, many of whom had failed medical, laser, and prior surgical treatments. 
The EX-PRESS Glaucoma Filtration Device
The EX-PRESS Glaucoma Filtration Device is intended to reduce IOP in glaucoma patients where medical and conventional surgical treatments have failed. The device is a miniature (<3 mm long) aqueous shunt composed of medical-grade stainless steel 10 and is fully biocompatible with the eye 10 (see Figure 1 ). It has a spur to prevent extrusion and an end-plate to prevent intrusion into the anterior chamber. The trans-scleral miniature tube delivers aqueous from the anterior chamber to the subscleral and subconjunctival spaces, to form a filtration bleb in a similar manner to trabeculectomy.
Postoperative outflow is controlled by the flow-modulating design. 11 Its standardized ostium size allows a more reproducible channel for fluid to drain out of the anterior chamber into the subconjunctival space.
The EX-PRESS device also offers the advantage of being less invasive than other techniques: implantation does not require scleral or iris tissue removal and requires a small point of entry into the anterior chamber. The device is implanted under a partial-thickness scleral flap that provides additional resistance to aqueous outflow and minimizes the risk for conjunctival erosion. 12 The operative time can be less than trabeculectomy and the procedure does not require the acquisition of a new skill set for many glaucoma surgeons, rather just the refinement of a few procedural steps accounting for the standardized ostium. The EX-PRESS device implantation procedure standardizes the sclerostomy. As a result of the lumen remaining constant, aqueous flow is adjusted by the number and tightness of the sutures used to close the scleral flap without having to consider a varying sclerectomy opening. Since there is no need to perform an iridectomy, the procedure should result in less inflammation. 13 Flow dynamics modeling has been used to optimize trabeculectomy and glaucoma-filtration devices. The success of implantation of glaucoma filtration devices depends on the formation of an improved outflow facility from the eye. A computational model has been developed describing fluid flow in the eye after glaucoma surgery. 3 According to this model, failure of IOP control is more directly related to decreases in hydraulic conductivity, resulting from scar formation, than to decreased absorption. The success of glaucoma surgery therefore depends on the hydraulic conductivity of the fibrous cap that develops around the bleb. Small, encapsulated blebs are less likely to be effective at allowing fluid to move into and be absorbed by subconjunctival tissue, and expose tissues to high pressures, particularly directly above the bleb. This is believed to initiate an ischemic tissue remodeling response, a reduction of hydraulic conductivity, and an elevation of IOP. High blebs are less likely to undergo remodeling but may lead to hypotonous eyes. 3 A low, diffuse bleb is therefore the ultimate goal of glaucoma-implant surgery.
The engineering of the EX-PRESS device improves flow dynamics and provides the surgeon lumenal control in their filtration surgery (see Figure 2 ).
Figure 1: The EX-PRESS ® Glaucoma Filtration Device
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Figure 2: Engineering of Lumenal Control in the EX-PRESS ® Device
How is lumenal control achieved? 
AH = aqueous humor.
Its length is designed to scan the sclera and enter the anterior chamber. The vertical slot in the end-plate is designed to direct aqueous flow posteriorly and facilitate the generation of a low-lying, diffuse bleb. US OPHTHALMIC REVIEW resistance is the diameter of a tube's internal lumen, i.e. a small change in diameter leads to a large inverse change in resistance.
The EX-PRESS device acts as a simple flow resistor and in a flow dynamics study, created a relatively constant resistance to flow. 14 The P-200 model with the larger internal lumen gave the highest flow rate and generated the least resistance to flow. Compared with the P-50 model, the flow rates were statistically significant (p<0.0001) at all pressure levels. All models tested showed higher flow rates per unit pressure than the outflow facility of a healthy human eye. It has been postulated that the lower rate of hypotony of the EX-PRESS device compared with trabeculectomy can be explained by the resistance to flow that is offered by the 50 μm lumen of the shunt. In trabeculectomy, the smallest scleral punch available is approximately 750 μm and that is only if one punch alone is used to make the incision.
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Clinical Studies of the EX-PRESS Device
Several studies to date have demonstrated that the EX-PRESS device has equivalent efficacy to trabeculectomy, but its flow dynamics confer advantages (see Table 1 group. No significant differences were objectified in success between both groups after the first week. 17 In an evaluation of the EX-PRESS device in refractory postpenetrating keratoplasty glaucoma, the complete success rate was 86 %. After implantation of the EX-PRESS device, clear grafts remained clear and edematous grafts became clearer. 18 In a five-year extension of a randomized study (n=78), 19 
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There is also evidence from previous studies of quicker VA recovery following EX-PRESS implantation: Good and Kahook found that VA returned to baseline by 1 week in the EX-PRESS device group compared with 1 month in the trabeculectomy group. 22 The Sugiyama study found that VA was significantly poorer from 1 week to 3 months in the trabeculectomy group while it was stable in the EX-PRESS device group for 12 months of follow up.
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Summary and Concluding Remarks
There is a need for improved surgical treatment options in glaucoma patients, especially those in which a procedure and medications have already failed. The strategy for managing patients who have experienced a failed trabeculectomy or corneal scarring can be challenging. The EX-PRESS device offers another option for these glaucoma patients.
Implanting the device in the correct location and entering at the iris plane are important to reach optimal outcomes.
Results of retrospective and prospective clinical studies demonstrate that implantation of the EX-PRESS device has similar success rates as trabeculectomy, but lower rates of hypotony and choroidal effusions.
The EX-PRESS device provides a more consistent flow of aqueous than trabeculectomy, and the bleb is low and diffuse, perhaps related to the fact that the egress of aqueous is more posterior with the EX-PRESS than with a manually created sclerostomy (see Figures 1 and 2) . In summary, the EX-PRESS device offers a step toward the standardization of aqueous outflow that is consistent with the trend in ocular surgery toward smaller incision microsurgery, and is associated with less inflammation, greater predictability with less hypotony, and more rapid visual recovery. n
CAUTION:
Federal law restricts this device to sale by or on the order of a physician.
INDICATION:
The EX-PRESS ® Glaucoma Filtration Device is intended to reduce intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed.
GUIDANCE REGARDING APPROPRIATE VERSION SELECTION:
Prior clinical studies were not designed to compare the various versions of the EX-PRESS Glaucoma Filtration Device. The selection of the appropriate version is according to the doctor's discretion.
CONTRAINDICATIONS:
The use of this device is contraindicated if one or more of the following conditions exist:
• Presence of ocular disease such as uveitis, ocular infection, severe dry eye, and severe blepharitis.
• Pre-existing ocular or systemic pathology that, in the opinion of the surgeon, is likely to cause postoperative complications following implantation of the device.
• Patients diagnosed with angle closure glaucoma.
WARNINGS/PRECAUTIONS:
• The surgeon should be familiar with the instructions for use.
• The integrity of the package should be examined prior to use and the device should not be used if the package is damaged and sterility is compromised.
• This device is for single use only.
• Magnetic resonace imaging of the head is permitted, however not recommended, in the first two weeks postimplantation.
ATTENTION:
Reference the Directions for Use labeling for a complete listing of indications, warnings, precautions, complications, and adverse events.
